Ironwood Pharmaceuticals (IRWD) Free Cash Flow (2010 - 2026)

Ironwood Pharmaceuticals has reported Free Cash Flow for 17 years, with the latest figure at $5.1 million in Q1 2026.

• Quarterly Free Cash Flow fell 74.3% year-over-year to $5.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $112.2 million (up 43.1% YoY) and the FY2025 annual result came in at $127.0 million, up 22.83% from the prior year.
• Free Cash Flow eased to $5.1 million in Q1 2026 per IRWD's latest filing, from $74.6 million in the prior quarter.
• Over five years, Free Cash Flow peaked at $80.2 million in Q1 2023 and troughed at -$15.1 million in Q2 2025.
• A 5-year average of $40.7 million and a median of $35.6 million in 2023 frame the typical range for Free Cash Flow.
• The widest YoY moves for Free Cash Flow: up 390.18% in 2025, down 145.11% in 2025.
• Over 5 years, Free Cash Flow stood at $79.2 million in 2022, then tumbled by 55.03% to $35.6 million in 2023, then sank by 57.29% to $15.2 million in 2024, then surged by 390.18% to $74.6 million in 2025, then slumped by 93.13% to $5.1 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered $5.1 million, $74.6 million, and $47.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.